NUS1関連疾患ののフェノタイプスペクトル:ケースシリーズ
Saumel Ahmadi1, Natalie Fulton1, Michael Morrissey1
1Division of Pediatric Neurology, Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Annals of the Child Neurology Society
|February 20, 2026
まとめ
NUS1遺伝子の病原性変異は,ドース症候群を含むと関連しています. これらの変異は,患者におけるモノモルフのテータ活性に関する特定のEEGパターンと関連しています.
科学分野:
- 遺伝学 遺伝学とは
- 神経学 神経学とは
- エピレプシの研究研究
背景:
- ミオクロニックおよびアトニック発作 (EMAtS) による,またはドース症候群 (Doose syndrome) は,子供の時に発生する希少なである.
- Nogo-B受容体 (NgBR) をコードするNUS1遺伝子は,コレステロール生物合成に役割を果たしています.
- 病原性NUS1変種は,運動障害とと関連しているが,そのスペクトルとEEG現象型は完全に理解されていない.
研究 の 目的:
- NUS1関連疾患の患者におけるエピレプシーとEEGのフェノタイプを特徴付ける.
- NUS1変種と,EMATSのような特定の症候群の関連性を調査する.
主な方法:
- NUS1関連疾患を有する5人の患者の単一センター症例シリーズを分析した.
- 臨床データ,の診断,遺伝的変異,そしてEEGの発見をレビューした.
主要な成果:
- 3人の患者はEMATSの基準を満たし,他の患者はより軽度の一般性を発症しました.
- 4人の患者は病原性NUS1の変異体を持ち,1人は意味不明の変異体を持っていた.
- 患者は正常から軽度の発達遅延,正常な脳MRI,および1歳から7歳までの発作発症を示した.
- 4人の患者のEEGは,一般的なスパイク波放電と,不変単型テータ活動の一貫したパターンを明らかにしました.
- 発作はレベチラセタムおよび/またはバルプロ酸に良好な反応を示した.
結論:
- NUS1の変種は,一般的なのフェノタイプと関連しています.
- モノモルフのセータ活動による不変のEEGパターンは,NUS1に関連するの特徴です.
キーワード:
ドース症候群 (Doose syndrome) とは,ドース症候群 (Doose syndrome) とは,ドース症候群 (Doose syndrome) とは,ドース症候群 (Doose syndrome) とは,ドース症候群 (Doose syndrome) とは,ドース症候群 (Doose syndrome) とは,ドース症候群 (Doose syndrome) とは,ドース症候群 (Doose syndrome) とはEEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,E,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,EEG,E,E,E,E,E-E-E-E-E-E-E-E-E-E-E-E-E-E-E-E-E-MEAIDシンドロームとはNUS1は1ドルでした.エピレプシー エピレプシーミオクロニック・アトニック発作による.
関連する概念動画
01:13Seizures: Classification
1.8K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.8K
01:24Epilepsy and Seizures: Overview
1.4K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.4K
01:20Antiepileptic Drugs: Potassium Channel Activators
744
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
744
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
982
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
982
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.4K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.4K
01:14Antiepileptic Drugs: Glutamate Antagonists
1.0K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.0K